GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
20.85
0.00 (0.00%)
At close: 12:09PM EDT
Stock chart is not supported by your current browser
Previous close20.85
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume1
Avg. volume2,834
Market cap102.155B
Beta0.89
PE ratio (TTM)75.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.09 (5.23%)
Ex-dividend date2018-05-10
1y target estN/A
Trade prices are not sourced from all markets
  • Calculating The Intrinsic Value Of GlaxoSmithKline plc (LON:GSK)
    Simply Wall St.19 hours ago

    Calculating The Intrinsic Value Of GlaxoSmithKline plc (LON:GSK)

    How far off is GlaxoSmithKline plc (LON:GSK) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks2 days ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Bloomberg4 days ago

    Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player

    GlaxoSmithKline Plc’s HIV venture wants to use less burdensome forms of treatment to unseat rival Gilead Sciences Inc. and become the top player in the $26 billion-a-year market in the mid-2020s. “If our pipeline and our competitors’ pipelines play out as we’re expecting, that’s our aim,” Deborah Waterhouse, chief executive officer of ViiV Healthcare, told journalists at a briefing Wednesday in London. Glaxo and partner Pfizer Inc. are taking on Gilead with a strategy to develop two-drug HIV combinations rather than the three-drug regimens that have been the standard for many years.

  • GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
    Reuters5 days ago

    GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

    GlaxoSmithKline (GSK.L) is taking its fight with Gilead Sciences (GILD.O) for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK's majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year (19.8 billion pounds) HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.

  • Reuters - UK Focus5 days ago

    GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

    GlaxoSmithKline (Other OTC: GLAXF - news) is taking its fight with Gilead Sciences (NasdaqGS: GILD - news) for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK's majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.

  • Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
    Zacks6 days ago

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

  • Large Cap Pharma Stock Outlook: Short-Term Struggle Likely
    Zacks7 days ago

    Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

    Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

  • Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
    Zacks9 days ago

    Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

    Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

  • Company News For Jun 15, 2018
    Zacks9 days ago

    Company News For Jun 15, 2018

    Companies In The News are: ETSY,RCL,MYL,GSK,TWTR

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks10 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
    Motley Fool10 days ago

    Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc

    Which big pharma stock wins in a head-to-head comparison?

  • Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV
    Investor's Business Daily10 days ago

    Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV

    GlaxoSmithKline popped Thursday after its two-drug HIV treatment proved non-inferior to a three-drug regimen using medicine from Gilead Sciences. But analysts say Glaxo is unlikely to get much share from Gilead.

  • Mylan (MYL) to Get CRL Again for Generic Advair from FDA
    Zacks10 days ago

    Mylan (MYL) to Get CRL Again for Generic Advair from FDA

    Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

  • FDA Rejects Mylan’s Generic Advair Again, Stock Falls
    Market Realist10 days ago

    FDA Rejects Mylan’s Generic Advair Again, Stock Falls

    On June 13, Mylan (MYL) announced that the FDA didn’t approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination. The FDA cited “minor deficiencies” in Mylan’s ANDA (abbreviated new drug application) for its generic Advair, which was first dismissed by the FDA in March 2017.

  • Reuters - UK Focus10 days ago

    BUZZ-Mylan: Out of breath as delay feared for generic Advair

    ** Shares of Mylan NV down 4.4 pct to $39.83 in Thurs trading ** Co late on Wed said U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug ...

  • GSK's two-drug HIV treatment meets main goal in late stage studies
    Reuters11 days ago

    GSK's two-drug HIV treatment meets main goal in late stage studies

    The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK's majority-owned ViiV Healthcare said on Thursday. It said its push for two-drug regimens addressed long-term toxicity concerns of people living with HIV by reducing the number of medicines. Rival Gilead Sciences in February won U.S. Food and Drug Administration approval for Biktarvy, a triple-combination HIV treatment, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

  • Reuters - UK Focus11 days ago

    GSK's two-drug HIV treatment meets main goal in late stage studies

    GlaxoSmithKline (Other OTC: GLAXF - news) 's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field. The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK's majority-owned ViiV Healthcare said on Thursday. It said its push for two-drug regimens addressed long-term toxicity concerns of people living with HIV by reducing the number of medicines.

  • MarketWatch11 days ago

    ViiV Healthcare reports positive results for late-stage HIV trials

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.

  • The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

    The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

  • A Look At The Fair Value Of GlaxoSmithKline plc (LON:GSK)
    Simply Wall St.11 days ago

    A Look At The Fair Value Of GlaxoSmithKline plc (LON:GSK)

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to forecast the attractiveness of GlaxoSmithKline plc (LSE:GSK) as an investment opportunity. If you wantRead More...

  • Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler
    Investor's Business Daily11 days ago

    Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler

    Mylan shares plunged late Wednesday after the FDA identified "minor deficiencies" in its application for a generic copy of GlaxoSmithKline's drug Advair.

  • Tory donor Odey seeks Tungsten chiefs' ousting
    Sky News11 days ago

    Tory donor Odey seeks Tungsten chiefs' ousting

    The billionaire hedge fund manager and Tory donor Crispin Odey has declared war on the board of a London-listed‎ electronic invoicing group in a bid to oust its bosses. Sky News has learnt that Odey Asset Management, which is one of the largest shareholders in Tungsten Corporation (Other OTC: TGTNF - news) , is demanding the scalps of chairman Nick Parker‎ and Richard Hurwitz, its chief executive. A meeting‎ of Tungsten (Stuttgart: 18580767.SG - news) 's directors has been convened for Thursday to discuss Odey's demands, according to insiders.

  • Top Stock Reports for Chevron, Glaxo & T-Mobile
    Zacks11 days ago

    Top Stock Reports for Chevron, Glaxo & T-Mobile

    Top Stock Reports for Chevron, Glaxo & T-Mobile

  • GSK says vaccine business president to leave by year-end
    Reuters12 days ago

    GSK says vaccine business president to leave by year-end

    Roger Connor, president of its global manufacturing and supply division since 2012, would replace Debruyne on September 1. Debruyne has held a number of roles during his career at GlaxoSmithKline, including general manager in the Netherlands and Italy and senior vice president of the company's pharmaceuticals business in Europe. CEO Emma Walmsley said earlier this year she was increasingly confident the company would be able to drive sales and profit growth over the next few years, helped by newer products such as its successful new shingles vaccine Shingrix.

  • Reuters - UK Focus12 days ago

    GSK says vaccine business president to leave by year-end

    GlaxoSmithKline Plc (Other OTC: GLAXF - news) said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year. Roger Connor, president of its global manufacturing and supply division since 2012, would replace Debruyne on September 1. Debruyne has held a number of roles during his career at GlaxoSmithKline, including general manager in the Netherlands and Italy and senior vice president of the company's pharmaceuticals business in Europe.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes